Interional Application No PCT/IB2005/000700

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 CO7K7/06 CO7K CO7K14/47 CO7K14/435 CO7K16/00 IPC 7 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** MinImum documentation searched (classification system followed by classification symbols) **CO7K** IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data, BIOSIS C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category ° DICKINSON D P ET AL: "cDNA cloning of an 17,19, abundant human lacrimal gland mRNA 44-46 encoding a novel tear protein." CURRENT EYE RESEARCH. APR 1996, vol. 15, no. 4, April 1996 (1996-04), pages 377-386, XP009035462 ISSN: 0271-3683 in particular see Fig. 1-2 and page 1-56 Α 383-384 the whole document Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the International filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention "E" earlier document but published on or after the International "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the citation or other special reason (as specified) document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled in the art. "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 07/06/2005 10 May 2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Vix, 0 Fax: (+31-70) 340-3016

0.40====	N DOCUMENTS CONSIDERED TO BE RELEVANT		5/000/00
C.(Continua Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
A	FIRLA BEATE ET AL: "Extracellular cysteines define ectopeptidase (APN, CD13) expression and function" FREE RADICAL BIOLOGY AND MEDICINE, vol. 32, no. 7, 1 April 2002 (2002-04-01), pages 584-595, XP002293336 ISSN: 0891-5849 the whole document		1-8,23, 50-56
A	EP 1 216 707 A (PASTEUR INSTITUT) 26 June 2002 (2002-06-26) cited in the application the whole document		1-56
A .	WO 98/37100 A (ROUGEOT CATHERINE; PASTEUR INSTITUT (FR); ROUGEON FRANCOIS (FR)) 27 August 1998 (1998-08-27) the whole document		1-56
		· · .	
· ·			
	·		
		•	
•			
· .			·
			,
		,	
,			

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 57

Reach-through compound:

Claim 57 relate to the use of an "agent" that "modulates the interaction between endogenous BPLP protein and a membrane metallopeptidase". As such, present claims 57 relate to a "use of a compound" only defined by reference to its potential interaction with different polypeptide and identified using screening methods.

The claim covers the use of all products having this characteristic or property, whereas the application provides support and/or disclosure within the meaning of Article 5 and 6 PCT for none such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity.

A meaningful search cannot be established because it is not possible to determine if any of the presently known substances is falling under the terms of these "modulators" use claims.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

mational application No.

PCT/IB2005/000700

inve	i regard intion, th	to any nucleotide ne international sea	and/or amino arch was carri	acid sequence discled out on the basis	losed in the i	international	application	and necessa	ry to the claim	ed
a.	type o	of material				•	•			
	X	a sequence listin	ng							
		table(s) related to	o the sequenc	ce listing	•		·		•	
b.		t of material								
	X	in written format								
	X	in computer reac	dable form	_						
c.	time c	of filling/furnishing								
	x	_	international a	application as filed						
	X			ional application in c	omnuter res	 Idable form				
		•		Authority for the pu						
	٠	Milliono e e e e e e	dona's cons	Additionly for all pa-	pose of our	ICH				
	or π	urnisnea, the requi	rea statement	an one version or co ts that the information eyond the application	in the sub:	sequent or a	dditional co	nies is identic	eto has been fall to the	filed e
Δdd	iiiional c	omments:							·	
Muu	Muia v	Onnients.								
					•					
										-
					·	-				
			•							
								·		
		•		•				•		
				•						
	•							,		
							· •			
		•				•				
									•	
						•				
							٠			
						•		•		
				•					•	



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
F V -7
2. X Claims Nos.: 57 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of Invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely pald by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

formation on patent family members

Interional Application No PCT/IB2005/000700

Patent document cited in search report		Publication date		Patent family member(s)	Publicat date	Publication date	
EP 1216707	А	26-06-2002	EP	1216707 /	1 26-06-	-2002	
			AT	288763			
			CA	2431913 /	1 04-07·	-2002	
			CA	2431916 A	1 04-07·	-2002	
			CN	1482917 /	17-03	-2004	
			CN	1482918 /	17-03	-2004	
	-		DE	60018085 [17-03·	-2005	
•			EP	1343519 /	17-09	-2003	
			EP	1343520 /	17-09	-2003	
			WO	02051434 /		-2002	
			WO	02051435 /	\2 04-07·	-2002	
	•		JP	2004532181	21–10	-2004	
,			JP	2004530640	07-10		
			US	2004116342			
			US	2004092486	13-05	-2004	
WO 9837100	Α	27-08-1998	US	2002019008	14-02	-2002	
			AU	6721998			
			CA	2281912	1 27-08	-1998	
	·		WO	9837100 /	\2 27-08	-1998	
			. EP	1007566	14-06	-2000	
•			US	2002198361	1 26-12	-2002	
			US	2003195155	16-10-	-2003	
		•	US	2004047805	\1 11-03·	-2004	